Edited by E. Hollander and D.J. Stein. 372 pp. New York, John Wiley, 1995. $95. ISBN 0-471-95328-8.
When the Dutch pharmaceutical firm Solvay Duphar was in theprocess of developing the antiaggressive drug eltoprazine, itapproached a number of clinicians in Europe and America to discussclinical testing. The drug, a serenic compound — a newclass of psychoactive compounds with apparently unique centralnervous system activity — appeared to reduce violencein all animal models, but it was not clear what kind of humanaggression would be mitigated by its use. Would highly impulsiveoutpatients experience a reduction in temper outbursts? If so,how would one measure this? Perhaps brain-damaged patients confinedto a ward would . . . [Full Text of this Article]
Previous
